Associated Genetic Biomarkers
Associated Diseases

Overview

Location [1]
2q35
Protein [2]
BRCA1-associated RING domain protein 1
Synonyms [1]
-

BRCA associated RING domain 1 (BARD1) is a gene that encodes a protein that binds to BRCA1 at its N-terminal and functions in regulating cell growth and tumor suppression. Missense mutations, nonsense mutations, silent mutations, frameshift insertions and deletions, and in-frame deletions are observed in cancers such as esophageal cancer, intestinal cancer, and ovarian cancer.

BARD1 is altered in 1.07% of all cancers with lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, bladder urothelial carcinoma, and cutaneous melanoma having the greatest prevalence of alterations [3].

BARD1 GENIE Cases - Top Diseases

The most common alterations in BARD1 are BARD1 Mutation (0.91%), BARD1 Deletion (0.07%), BARD1 Frameshift (0.07%), BARD1 Nonsense (0.06%), and BARD1 L359_P365del (0.06%) [3].

BARD1 GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of BARD1 in Diseases

Prostate Carcinoma +

Malignant Solid Tumor +

Breast Carcinoma +

Ovarian Carcinoma +

Prostate Adenocarcinoma +

Primary Peritoneal Carcinoma +

Fallopian Tube Carcinoma +

Urothelial Carcinoma +

Pancreatic Adenocarcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Endometrial Carcinoma +

Non-Small Cell Lung Carcinoma +

Cervical Carcinoma +

Clear Cell Renal Cell Carcinoma +

Gastric Adenocarcinoma +

Non-Hodgkin Lymphoma +

Small Cell Lung Carcinoma +

Bladder Urothelial Carcinoma +

Esophageal Adenocarcinoma +

Colorectal Carcinoma +

Cholangiocarcinoma +

High Grade Ovarian Serous Adenocarcinoma +

Pancreatic Carcinoma +

Gastric Carcinoma +

Gastrointestinal Stromal Tumor +

Head And Neck Squamous Cell Carcinoma +

Osteosarcoma +

Pancreatic Ductal Adenocarcinoma +

Soft Tissue Sarcoma +

Squamous Cell Lung Carcinoma +

Melanoma +

Bladder Carcinoma +

Colorectal Adenocarcinoma +

Malignant Intestinal Neoplasm +

Esophageal Carcinoma +

Biliary Tract Carcinoma +

Malignant Ovarian Epithelial Tumor +

Malignant Esophagogastric Neoplasm +

Bile Duct Adenocarcinoma +

Invasive Breast Carcinoma +

Ampulla Of Vater Carcinoma +

Anal Carcinoma +

B-Cell Non-Hodgkin Lymphoma +

Diffuse Large B-Cell Lymphoma +

Ewing Sarcoma +

Head And Neck Carcinoma +

Hepatocellular Carcinoma +

Histiocytic And Dendritic Cell Neoplasm +

Kidney Carcinoma +

Leiomyosarcoma +

Low Grade Ovarian Serous Adenocarcinoma +

Malignant Gastric Neoplasm +

Malignant Mesothelioma +

Malignant Small Intestinal Neoplasm +

Mantle Cell Lymphoma +

Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +

Mesothelioma +

Multiple Myeloma +

Neuroblastoma +

Ovarian Clear Cell Adenocarcinoma +

Penile Carcinoma +

Renal Cell Carcinoma +

Rhabdomyosarcoma +

Uveal Melanoma +

Vaginal Carcinoma +

Vulvar Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.